Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for renal outcomes in children with chronic kidney disease
IRCT20200608047689N4Phase 3Recruiting
- Sponsor
- Guilan University of Medical Sciences
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dapagliflozin in chronic kidney disease (CKD) (2 arms), sponsored by Guilan University of Medical Sciences. Primary endpoint: Change in estimated glomerular filtration rate. Started Nov 2025; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on IRCT20200608047689N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200608047689N4.